Clinical Trial Update: Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199) [Phase 2]

View source ↗

Summary

A Phase 2 study of pembrolizumab (MK-3475) in participants with metastatic castration-resistant prostate cancer has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2023-03-24